Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | 0.026 | 0.0777 | 1 |
Trichomonas vaginalis | ferritin, putative | 0.0019 | 0.0003 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0724 | 0.2268 | 1 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0724 | 0.2268 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.0354 | 0.1081 | 0.4768 |
Echinococcus granulosus | tumor protein p63 | 0.0354 | 0.1081 | 0.4768 |
Mycobacterium ulcerans | pantoate--beta-alanine ligase | 0.313 | 1 | 1 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0724 | 0.2268 | 1 |
Echinococcus granulosus | ferritin | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | apoferritin-2 | 0.0019 | 0.0003 | 0.0014 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0056 | 0.0123 | 0.1587 |
Toxoplasma gondii | pantoate-beta-alanine ligase | 0.313 | 1 | 0.5 |
Echinococcus multilocularis | ferritin | 0.0019 | 0.0003 | 0.0014 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.026 | 0.0777 | 1 |
Schistosoma mansoni | ferritin | 0.0019 | 0.0003 | 0.0014 |
Brugia malayi | MH2 domain containing protein | 0.026 | 0.0777 | 1 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0132 | 0.0367 | 0.1619 |
Wolbachia endosymbiont of Brugia malayi | bacterioferritin/cytochrome b1 | 0.0019 | 0.0003 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0038 | 0.0066 | 0.0852 |
Schistosoma mansoni | thyroid hormone receptor | 0.0143 | 0.0401 | 0.1769 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0143 | 0.0401 | 0.1769 |
Mycobacterium tuberculosis | Pantoate--beta-alanine ligase PanC (pantothenate synthetase) (pantoate activating enzyme) | 0.313 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0132 | 0.0367 | 0.1619 |
Schistosoma mansoni | ferritin light chain | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | ferritin light chain | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.0066 | 0.0292 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0056 | 0.0123 | 0.1587 |
Treponema pallidum | bacterioferrin (TpF1) | 0.0019 | 0.0003 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0056 | 0.0123 | 0.1587 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0.0123 | 0.1587 |
Schistosoma mansoni | ferritin | 0.0019 | 0.0003 | 0.0014 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.011 | 0.1409 |
Schistosoma mansoni | ferritin | 0.0019 | 0.0003 | 0.0014 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0132 | 0.0367 | 0.1619 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.0066 | 0.0852 |
Onchocerca volvulus | 0.0052 | 0.011 | 0.5 | |
Echinococcus granulosus | expressed protein | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | apoferritin-2 | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0052 | 0.011 | 0.0483 |
Schistosoma mansoni | thyroid hormone receptor | 0.0143 | 0.0401 | 0.1769 |
Echinococcus multilocularis | expressed protein | 0.0019 | 0.0003 | 0.0014 |
Schistosoma mansoni | ferritin | 0.0019 | 0.0003 | 0.0014 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = -5.22 % | Inhibition of electric eel AChE at 2 mg/ml by Ellman's method | ChEMBL. | 23062825 |
Inhibition (binding) | = -0.35 % | Inhibition of horse BChE at 2 mg/ml by Ellman's method | ChEMBL. | 23062825 |
Inhibition (ADMET) | = 114.4004656 % | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | ChEMBL. | 23571415 |
Inhibition (ADMET) | = 125.4721051 % | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | ChEMBL. | 23571415 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.